Ethr from mycobacterium tuberculosis in complex with compound bdm14744 Deposition Author(s): Aumercier, M. , Baulard, A.R. , Bifani, P. , Carette, X. , Delcroix, G. , Deprez, B. , Deprez-Poulain, R. , Desroses, M. , Dirie, B. , Frenois, F. , Leroux, F. , Locht, C. , Mathys, V. , Singhal, A. , Villeret, V. , Willand, N. , Willery, E.
Date: 2009-01-30 Method: X-RAY DIFFRACTION Resolution: 1.7 Å Organism(s): Mycobacterium Tuberculosis Sequences Data: 3G1L_A
Ethr from mycobacterium tuberculosis in complex with compound bdm31381 Deposition Author(s): Aumercier, M. , Baulard, A.R. , Bifani, P. , Carette, X. , Delcroix, G. , Deprez, B. , Deprez-Poulain, R. , Desroses, M. , Dirie, B. , Frenois, F. , Leroux, F. , Locht, C. , Mathys, V. , Singhal, A. , Villeret, V. , Willand, N. , Willery, E.
Date: 2009-01-30 Method: X-RAY DIFFRACTION Resolution: 1.7 Å Organism(s): Mycobacterium Tuberculosis Sequences Data: 3G1M_A
Ethr from mycobacterium tuberculosis in complex with compound bdm14500 Deposition Author(s): Aumercier, M. , Baulard, A.R. , Bifani, P. , Carette, X. , Delcroix, G. , Deprez, B. , Deprez-Poulain, R. , Desroses, M. , Dirie, B. , Frenois, F. , Leroux, F. , Locht, C. , Mathys, V. , Singhal, A. , Villeret, V. , Willand, N. , Willery, E.
Date: 2009-01-30 Method: X-RAY DIFFRACTION Resolution: 1.85 Å Organism(s): Mycobacterium Tuberculosis Sequences Data: 3G1O_A
Ethionamide boosters part 2: combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole ethr inhibitors. Deposition Author(s): Baulard, A.R. , Blondiaux, N. , Brodin, P. , Christophe, T. , D Prez, B. , Desroses, M. , Flament, M.P. , Flipo, M. , Jeon, H.K. , Lecat-Guillet, N. , Leroux, F. , Locht, C. , Mathys, V. , Piveteau, C. , Siepmann, J. , Soror, S.H. , Villemagne, B. , Villeret, V. , Willand, N. , Wintjens, R. , Wohlkonig, A.
Date: 2011-06-09 Method: X-RAY DIFFRACTION Resolution: 1.87 Å Organism(s): Mycobacterium Tuberculosis Sequences Data: 3SDG_A
Ethionamide boosters part 2: combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole ethr inhibitors. Deposition Author(s): Baulard, A.R. , Blondiaux, N. , Brodin, P. , Christophe, T. , D Prez, B. , Desroses, M. , Flament, M.P. , Flipo, M. , Jeon, H.K. , Lecat-Guillet, N. , Leroux, F. , Locht, C. , Mathys, V. , Piveteau, C. , Siepmann, J. , Soror, S.H. , Villemagne, B. , Villeret, V. , Willand, N. , Wintjens, R. , Wohlkonig, A.
Date: 2011-06-13 Method: X-RAY DIFFRACTION Resolution: 2.31 Å Organism(s): Mycobacterium Tuberculosis Sequences Data: 3SFI_A